产品说明
一般描述
GSK0660 has antiangiogenic property in oxygen-induced retinopathy. It also regulates tumor necrosis factor-α (TNFα)-induced inflammation in human retinal microvascular endothelial cells (HRMECs).
应用
GSK0660 has been used to study the effects of bezafibrate (BZA) on hypertrophy.
包装
5 mg in glass bottle
生化/生理作用
GSK0660 is a potent PPARβ/δ antagonist with a pIC50 of 6.8 (160 nM). GSK0660 is nearly inactive on PPARα and PPARγ with IC50s greater than 10 μM.
特点和优势
This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
基本信息
| 经验(实验)分子式 | C19H18N2O5S2 |
| 分子量 | 418.49 |
| MDL编号 | MFCD12828770 |
| PubChem化学物质编号 | 329799945 |
| NACRES | NA.77 |
产品性质
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| 颜色 | white to beige |
| 溶解性 | DMSO: 10 mg/mL, clear |
| 创始人 | GlaxoSmithKline |
| 储存温度 | 2-8℃ |
| SMILES string | COC(=O)c1sccc1S(=O)(=O)Nc2ccc(Nc3ccccc3)cc2OC |
| InChI | 1S/C19H18N2O5S2/c1-25-16-12-14(20-13-6-4-3-5-7-13)8-9-15(16)21-28(23,24)17-10-11-27-18(17)19(22)26-2/h3-12,20-21H,1-2H3 |
| InChI key | NDFKBGWLUHKMFY-UHFFFAOYSA-N |
安全信息
| 储存分类代码 | 13 - Non Combustible Solids |
| WGK | WGK 2 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
| 个人防护装备 | Eyeshields, Gloves, type N95 (US) |
